Skip to content

About us

Personalized Precision
with Patient Focus

RadioVaxX GmbH

„To see what you treat“

Theranostics has changed the way to see cancer.

Radioligands visualize uptake of anti cancer drugs into target lesions. Radioligands individualize side effect assessment by quantitating uptake into non-target lesions. Targeting tumor cells & surrounding tumor stroma results in higher sensitivity of detecting early lesions and progression at oligometastatic status

Theranostics improves staging and enables new strategies for follow-up care.

„From single entity to pan cancer solutions“

PSMA targeting revolutionizes the way to treat prostate cancer.
Targeting the tumor stroma establishes pan-cancer approaches.

Breaking resistance towards current standard treatements by integrating theranostic and immunemodulatroy approaches.

True precision by absolute quantitation of drug load and dynamic molcular tumor volume assesment.

„Enablement & Implementation into clinical Routine“

On site production of theranostic compounds requires a new level of clinical expertise.

Leading radiochemists can join your team, train at experienced theranostic centers and accompany set-up at individual sites world-wide.

Trouble shooting and fast time-to-response smoothen the implementation of theranostics at your site.

„Development of new anti-cancer compounds“

Theranostic compound development requires strong expertise in pre-conical development and translation into first in human treatments.

Learn from leading expert teams specialized in radioligand develoment until market launch for decades. Built on longstanding experience in molecular research / basic sciences, translational biomarker assessment in clinical trials and clinical routine experience from molecular registries.

To listen to specific needs, care for details and create fully customized solutions within multidisciplinary teams.

„Taking advantage of immune therapeutic approaches“

Decades of immunologic research and experience from clincal trials with checkpoint inhibitors in diverse indications result in deep insights in mode of actions and immunologic opportunities.

Real World registries in diverse cancer indications (lung, bladder, breast, prostate) have elucidated efficacy of immune modulatory drugs and tumor subtype dependance of immune action in molecular detail. Longterm survival in the advanced setting by theranostic or standard treatments requires reshape of cancer recognition and immune activation. Sequence and timing of treatment modalities is crucial for therapy success. Early indicators of treatment success or failure based on molecular assessments in vivo and in vitro to modulate the individual dynamcis in a patient oriented manner.